-The Hindu Vaccination is important to prevent a second wave Several people have questioned the emergency approval given to the indigenously developed COVID-19 vaccine. They have demanded efficacy data and cast aspersions on the regulatory machinery. Such views will only increase vaccine hesitancy. It is not the case that the vaccine developed indigenously is being pushed by vested interests, while the international vaccines are great. Questions have been raised about the Moderna and...

-The Indian Express The current scenario is ideal for policymakers and practitioners to drive home the importance of health spending and institutional development With the first batch of anti-COVID vaccines being rolled out, the mood of the nation seems to be upbeat as it bids farewell to the pain and anguish of last year. The emergency-use approval to the vaccine developed by Oxford University and the Swedish-British pharma major AstraZeneca, manufactured in...

-The Hindu Company releases fact sheet detailing possible adverse events and those who are eligible for the vaccine Those with any history of allergies, fever and bleeding disorder, on blood thinners and who are immunity compromised or on medication have been told by COVAXIN manufacturer Bharat Biotech not to take the vaccine. A statement uploaded on the company website on Monday said the vaccine was also contraindicated for pregnant/lactating women, those using other...

-Livemint.com/ PTI Icra expects the headline CPI inflation to decline to 4.6% in FY2022 from 6.4% in FY2021, while exceeding the mid-point of the Monetary Policy Committee's medium target of 4%, for the third consecutive year MUMBAI: Domestic rating agency Icra Ratings on Monday said it expects the country's real gross domestic product (GDP) to grow by 10.1% in FY2022. It, however, said the value of GDP in the next financial year will...

-The Hindu They advise against Covaxin, say there is no proof of efficacy. Several experts have raised concern over the “hasty approval” granted to the COVID-19 vaccines despite the lack of adequate efficacy data. The Central Drugs Standard Control Organisation on Sunday accorded approval for restricted emergency use of the Oxford COVID-19 vaccine Covishield, manufactured by the Serum Institute of India (SII), and the indigenously developed vaccine Covaxin of Bharat Biotech. “I’m completely unaware...